Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Dipyridamole (compound)


PubChem
Name: Dipyridamole
PubChem Compound ID: 3108
Description: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
Molecular formula: C24H40N8O4
Molecular weight: 504.626 g/mol
Synonyms:
Chilcolan; AIDS-029341; 4-26-00-03840 (Beilstein Handbook Reference); Stimolcardio; USAF GE-12; BAS 00818792; SPBio_002183; CAS-58-32-2; BRN 0068373; Apricor.
show more »
DrugBank
Identification
Name: Dipyridamole
Name (isomeric): DB00975
Drug Type: small molecule
Description: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
Synonyms:
Dipyudamine; Usaf Ge-12; Dipiridamol; Dipyridamol; Dypyridamol; Dipyridamine
Brand: Cleridium 150, Gulliostin, Prandiol 75, Coribon, Natyl, Piroan, Dipyridan, RA 8, Protangix, Aggrenox, Kurantil, Cardoxil, Cardioflux, Peridamol, Apricor, IV Persantine, Permiltin, Coroxin, Persantine, Persantin, RA-8, Corosan, Cleridium, Curantyl, Justpertin, Stenocardiol, Prandiol, Anginal, Coridil, Coronarine, Stenocardil, Chilcolan, Agilease, Apo-Dipyridamole Sc, Novo-Dipiradol, Stimolcardio, Apo-Dipyridamole Fc
Category: Vasodilator Agents, Phosphodiesterase Inhibitors, Platelet Aggregation Inhibitors
CAS number: 58-32-2
Pharmacology
Indication: For as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement and also used in prevention of angina.
Pharmacology:
Dipyridamole, a non-nitrate coronary vasodilator that also inhibits platelet aggregation, is combined with other anticoagulant drugs, such as warfarin, to prevent thrombosis in patients with valvular or vascular disorders. Dipyridamole is also used in myocardial perfusion imaging, as an antiplatelet agent, and in combination with aspirin for stroke...
show more »
Mechanism of Action:
Dipyridamole likely inhibits both adenosine deaminase and phosphodiesterase, preventing the degradation of cAMP, an inhibitor of platelet function. This elevation in cAMP blocks the release of arachidonic acid from membrane phospholipids and reduces thromboxane A2 activity. Dipyridamole also directly stimulates the release of prostacyclin, which in...
show more »
Absorption: 70%
Protein binding: 99%
Biotransformation: hepatic
Route of elimination: Dipyridamole is metabolized in the liver to the glucuronic acid conjugate and excreted with the bile.
Half Life: 40 minutes
Clearance: 2.3-3.5 mL/min/kg
Toxicity: Hypotension, if it occurs, is likely to be of short duration, but a vasopressor drug may be used if necessary. The oral LD50 in rats is greater than 6,000 mg/kg while in the dogs, the oral LD50 is approximately 400 mg/kg. LD50=8.4g/kg (orally in rat)
Affected organisms: Humans and other mammals
Interactions
Food interaction:
Coffee and tea can decrease the effect of dipyridamole.
Take with food to reduce irritation.
Drug interaction:
Ginkgo bilobaAdditive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
TopotecanThe p-glycoprotein inhibitor, Dipyridamole, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
TreprostinilThe prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Dipyridamole. Monitor for increased bleeding during concomitant thearpy. Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
FludarabineDipyridamole may decrease the effect of fludarabine.
AdenosineDipyridamole may increase the effect/toxicity of adenosine.

Targets


Transporters